Terlipressin versus albumin in paracentesis‐induced circulatory dysfunction in cirrhosis: A randomized study

Abstract

Terlipressin may be as effective as intravenous albumin in preventing paracentesis-induced circulatory dysfunction in patients with cirrhosis after therapeutic paracentesis.

Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study

“…Currently, the first line approach to refractory ascites is serial LVP up to every 2 weeks. Vasopressors have been used in patients with HRS [10][11][12][13] as well as for the prevention of post-paracentesis circulatory dysfunction with variable results [14][15][16][17][18]. It is possible that vasoconstrictors may reverse some of the pathogenic events that result in increased renal sodium retention and refractoriness to diuretic therapy.…”

“…Several studies have evaluated the efficacy of various vasopressors in patients with hepatorenal syndrome (HRS) [10][11][12][13]. Vasopressors have also been used for the prevention of post-paracentesis circulatory dysfunction with variable results [14][15][16][17][18]. Recently, various vasoconstrictors have been used in nonazotemic cirrhotic patients with ascites and showed an improvement in circulatory and renal function and sodium excretion [19][20][21].…”

Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study

“…Patients with HRS have marked circulatory dysfunction with splanchnic arterial vasodilatation resulting in severe renal vasoconstriction [3]. Several studies have evaluated the efficacy of various vasopressors in patients with post-paracentesis circulatory dysfunction [4][5][6][7], refractory ascites [8,9] and HRS [10][11][12][13].…”

AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis

“…More recently, the use of vasoconstrictors, including vasopressin, terlipressin, and midodrine, has been compared to the administration of HA after paracentesis [29][30][31][32][33] . However, the results of the few randomised clinical trials are variable, probably because of their very limited sample size, so that the clinical utility of vasopressors after paracentesis cannot be ascertained.…”